Journal article
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, C Colasacco, S Dacic, FR Hirsch, K Kerr, DJ Kwiatkowski, M Ladanyi, JA Nowak, L Sholl, R Temple-Smolkin, B Solomon, LH Souter, E Thunnissen, MS Tsao, CB Ventura Show all
Journal of Molecular Diagnostics | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. Objective: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. Design: The College of A..
View full abstractGrants
Awarded by Amgen